WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Aricept® Patch (donepezil transdermal system). Teikoku Pharma USA, Inc., a subsidiary of Teikoku Seiyaku Co., Ltd., and Eisai are seeking approval of the weekly Aricept Patch in the treatment of mild, moderate and severe stages of Alzheimer’s disease.
